Ann: Notice of Annual General Meeting/Proxy Form, page-3

I think it is disappointing that the board offer no validation except to say they will all go if they don't all stay.  The SP is 5c. The company will receive after fees are removed etc less than $1.9m of revenue from the R&D as previously stated by Mr Mower. It has less than 3 months revenue to continue. They can only raise 2.5m at this MC. They are announcing conference presentations and R&D but not FDA complications.  There are no new clients. Board members have not invested personally, have not explained any of their actions or poor decisions, FDA de novo is flawed and clinical results are poor. And all the board can do is say they will leave???  The Chairman had already told the big investors they had his word he would go.  What's to hang onto? SH never invested because of who the Board were they invested because there was good evidence and good leadership. Neither or which appear to be true.